Craig Surman

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/10750955/publications.pdf

Version: 2024-02-01

16	1,160	759233 12	996975 15
papers	citations	h-index	g-index

16	16	16	1037
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Effect of a Multi-Layer, Extended-Release Methylphenidate Formulation (PRC-063) on Sleep in Adults with ADHD: A Randomized, Double-Blind, Forced-Dose, Placebo-Controlled Trial Followed by a 6-month Open-Label Extension. CNS Drugs, 2021, 35, 667-679.	5.9	7
2	A prospective open-label trial of long-acting liquid methylphenidate for the treatment of attention deficit/hyperactivity disorder in intellectually capable adults with autism spectrum disorder. World Journal of Biological Psychiatry, 2020, 21, 274-290.	2.6	8
3	Atomoxetine increases fronto-parietal functional MRI activation in attention-deficit/hyperactivity disorder: A pilot study. Psychiatry Research - Neuroimaging, 2013, 211, 88-91.	1.8	31
4	Is Response to OROSâ€Methylphenidate Treatment Moderated by Treatment with Antidepressants or Psychiatric Comorbidity? A Secondary Analysis from a Large Randomized Double Blind Study of Adults with ADHD. CNS Neuroscience and Therapeutics, 2012, 18, 126-132.	3.9	14
5	The Effects of Lisdexamfetamine Dimesylate on Driving Behaviors in Young Adults With ADHD Assessed With the Manchester Driving Behavior Questionnaire. Journal of Adolescent Health, 2012, 51, 601-607.	2.5	21
6	A controlled study of a simulated workplace laboratory for adults with attention deficit hyperactivity disorder. Psychiatry Research, 2012, 200, 949-956.	3.3	14
7	The effects of lisdexamfetamine dimesylate on the driving performance of young adults with ADHD: A randomized, double-blind, placebo-controlled study using a validated driving simulator paradigm. Journal of Psychiatric Research, 2012, 46, 484-491.	3.1	51
8	A Randomized, 3-Phase, 34-Week, Double-Blind, Long-Term Efficacy Study of Osmotic-Release Oral System-Methylphenidate in Adults With Attention-Deficit/Hyperactivity Disorder. Journal of Clinical Psychopharmacology, 2010, 30, 549-553.	1.4	68
9	A 2009 update on adult ADHD. Current Attention Disorders Reports, 2009, 1, 131-136.	0.3	0
10	Update on adult attention-deficit/hyperactivity disorder. Current Neurology and Neuroscience Reports, 2008, 8, 484-489.	4.2	11
11	Functional Magnetic Resonance Imaging of Methylphenidate and Placebo in Attention-Deficit/Hyperactivity Disorder During the Multi-Source Interference Task. Archives of General Psychiatry, 2008, 65, 102.	12.3	190
12	Comparative acute efficacy and tolerability of OROS and immediate release formulations of methylphenidate in the treatment of adults with attention-deficit/hyperactivity disorder. BMC Psychiatry, 2007, 7, 49.	2.6	33
13	A Randomized, Placebo-Controlled Trial of OROS Methylphenidate in Adults with Attention-Deficit/Hyperactivity Disorder. Biological Psychiatry, 2006, 59, 829-835.	1.3	245
14	An Open-Label Trial of OROS Methylphenidate in Adults with Late-Onset ADHD. CNS Spectrums, 2006, 11, 390-396.	1.2	38
15	Behavior differences in drivers with attention deficit hyperactivity disorder: The driving behavior questionnaire. Accident Analysis and Prevention, 2005, 37, 996-1004.	5.7	85
16	A large, double-blind, randomized clinical trial of methylphenidate in the treatment of adults with attention-deficit/hyperactivity disorder. Biological Psychiatry, 2005, 57, 456-463.	1.3	344